Each tab is a request you typed. Every story shows the tickers it moves, whether it is confirmed, and why it landed in your feed.
Headlines link to their sources; summaries are written by The Market Standard. Rumors are unverified until they resolve. Nothing here is financial advice.
Major US indexes fell sharply on the day, with the Dow down about 1,100 points and the S&P 500 and Nasdaq sliding, as the headline links the selloff to Anthropic going public. The feed gives no further detail on the cause or the size of the move beyond the headline.
Minutes from the Fed's October meeting show policymakers expect a December rate increase and discussed faster tightening. Officials also flagged inflation risks tied to the AI infrastructure build-out.
U.S. stocks fell as artificial-intelligence shares kept sliding, even as Anthropic's record-breaking initial public offering took place. The IPO did not stop the selloff in AI names, which matters for holders of AI-exposed stocks.
TPG and Corpay are reported to be taking BILL Holdings private in a deal valued at about $6 billion. The headline alone gives no terms or confirmation from the companies, so holders should watch for an official announcement.
Celldex reported that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary and key secondary endpoints, and the company is discontinuing development in that indication. The drug showed a favorable safety profile in the study.
U.S. stocks closed lower, with the Dow Jones Industrial Average down 2.19%. The headline gives no cause, so the broader market move is the only confirmed detail.
TSMC and Samsung have reportedly suspended some chip shipments to Chinese customers following new US Commerce Department export controls. The move could affect revenue from China-linked chip demand for TSMC.
Intuit agreed to sell its Mailchimp email automation platform to Bending Spoons for $3.68 billion. The company also reported higher profit and revenue for its fiscal first quarter.
Fed Vice Chair Philip Jefferson said artificial intelligence is currently adding to inflation, and that any productivity gains from AI may only arrive in the future. The comments bear on how the Fed views the outlook for rates.
The Boston Beer Company named Phil Hodges as its President and Chief Executive Officer, according to a company press release. Founder Jim Koch will continue as Executive Chairman of the Board.
Standard BioTools stockholders approved all proposals tied to its merger with Treeline Biosciences and the sale of its Mass Cytometry business to Element Biosystems, an acquisition vehicle formed by GMT Venture Partners. The company announced the vote results itself, so the approvals are on the record.
Intuit reported first-quarter results that met analyst earnings estimates, with its Credit Karma unit hitting its guidance. The company also disclosed the sale of Mailchimp, with Bending Spoons S.p.A. named as the buyer.
President Trump reportedly suggested that Nvidia's Blackwell chips could eventually be sold to China. The headline gives no details on timing or conditions, so the impact on Nvidia's China sales outlook is unclear.
All 11 S&P 500 sectors declined on Thursday, with 10 falling by more than 1%. Cybersecurity stocks were the exception and rose against the broad selloff.
Gap cut its full-year sales outlook, now expecting roughly flat sales versus earlier guidance of a 1% to 1.5% increase, which the headline ties to warm fall weather. Investors should weigh the lowered revenue forecast for the apparel retailer.
Walmart filed an 8-K with the SEC reporting its results of operations and financial condition. The filing is the company's own disclosure of its latest financial results.
Wall Street closed sharply lower after Anthropic's debut failed to revive enthusiasm for AI stocks. The headline gives no further detail on the offering or index moves.
Gap cut its annual forecasts and flagged weak apparel demand heading into the holiday season. The headline alone does not give the size of the cut or the company's own statement.
Webull reported third-quarter GAAP earnings of $0.06 per share, $0.01 above estimates, and revenue of $218.72 million, $3.13 million above expectations. The results beat forecasts on both lines.
Post Holdings said Executive Chairman Robert Vitale is taking a medical leave of absence and that its board has named a director to take on interim duties. The change in leadership is relevant to holders of the stock.
Anthropic's shares began trading in its IPO, and the stock reportedly closed the first day at $97, up more than 17%. The source is a headline and short teaser, so the listing ticker and offering details are not confirmed here.
Anthropic, the AI company led by Dario Amodei, reportedly raised $81bn in an upsized public offering, and its shares rose 17% after a record Wall Street listing. The feed names no US ticker, so the listing symbol is not confirmed here.
The Federal Energy Regulatory Commission approved Cheniere's Sabine Pass LNG expansion project. The decision clears a regulatory hurdle for added liquefied natural gas export capacity, which matters to holders of LNG and its partnership CQP.
Goosehead Insurance said on November 9, 2026 that it would not timely file its quarterly report because it needs to restate prior financial statements, and the stock fell about 15%. A law firm has opened an investigation on behalf of shareholders.
UGI outlined a plan to separate its Global LPG business in the second half of 2027, with the remaining company targeting 6% to 8% EPS growth and more than $5 billion of investment. The separation reshapes the company and sets a multi-year growth outlook for holders.
Alibaba's third quarter 2026 slides show profitability up 260% with growth attributed to its AI cloud business. The figures come from the company's own earnings materials, so holders can treat them as the reported numbers.
Revolution Medicines reported updated Phase 1/2 data for RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel as a possible first-line treatment for metastatic pancreatic cancer, presented at the ENA Symposium in Barcelona.
Bausch + Lomb shares fell after a headline said an eye pain drug missed its trial endpoint. Only the headline is available, so the trial details and company response are not yet known.